Donepezil in treatment-resistant bipolar disorder
- PMID: 10386177
- DOI: 10.1016/s0006-3223(98)00320-5
Donepezil in treatment-resistant bipolar disorder
Abstract
Background: A considerable percentage of patients with bipolar disorder do not respond or do not tolerate conventional treatment. Cholinesterase (ChE) inhibitors have been suggested to possess depressogenic and antimanic properties.
Methods: We report a case series of treatment-resistant bipolar patients (n = 11) to whom we administered the ChE inhibitor donepezil. Four patients met criteria for current manic episode, 5 for mixed episode, 1 for hypomanic episode, and 1 for major depressive episode. Donepezil was added to current medication on an openlabel basis. Ratings were based on a retrospective chart review.
Results: Of the 11 patients, 6 (54.5%) demonstrated marked improvement (improvement in CGI-S > or = 2), 3 (27.2%) demonstrated slight improvement, 1 did not respond, and 1 did not tolerate the medication. Among those patients who had marked improvement (i.e., responders, n = 6), improvement was observed within 2 weeks or less in 5 of them (83%). Patients experienced only minor side effects.
Conclusions: These pilot data suggest the efficacy and safety of donepezil in the treatment of bipolar disorder. To our knowledge this is the first published report on the use of donepezil in the treatment of mood disorders. Controlled, randomized, double-blind studies are necessary to validate these preliminary observations.
Similar articles
-
Is donepezil useful for improving cognitive dysfunction in bipolar disorder?J Affect Disord. 2008 Apr;107(1-3):237-40. doi: 10.1016/j.jad.2007.07.027. Epub 2007 Sep 10. J Affect Disord. 2008. PMID: 17825922
-
Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders.J Clin Psychiatry. 2005 Jan;66(1):107-10. doi: 10.4088/jcp.v66n0115. J Clin Psychiatry. 2005. PMID: 15669896
-
A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania.Bipolar Disord. 2006 Feb;8(1):75-80. doi: 10.1111/j.1399-5618.2006.00243.x. Bipolar Disord. 2006. PMID: 16411983 Clinical Trial.
-
Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions.J Affect Disord. 2016 Jun;197:268-80. doi: 10.1016/j.jad.2016.03.034. Epub 2016 Mar 10. J Affect Disord. 2016. PMID: 27010579 Review.
-
Donepezil for mild and moderate Alzheimer's disease.Cochrane Database Syst Rev. 2000;(2):CD001190. doi: 10.1002/14651858.CD001190. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2000;(4):CD001190. doi: 10.1002/14651858.CD001190 PMID: 10796620 Updated. Review.
Cited by
-
Cholinesterase inhibitors for behavioral disturbance in dementia.Curr Psychiatry Rep. 2001 Jun;3(3):251-8. doi: 10.1007/s11920-001-0061-7. Curr Psychiatry Rep. 2001. PMID: 11353590 Review.
-
Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles.CNS Drug Rev. 2001 Winter;7(4):353-68. doi: 10.1111/j.1527-3458.2001.tb00204.x. CNS Drug Rev. 2001. PMID: 11830754 Free PMC article. Review.
-
Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis.Int J Mol Sci. 2021 Aug 27;22(17):9290. doi: 10.3390/ijms22179290. Int J Mol Sci. 2021. PMID: 34502198 Free PMC article. Review.
-
New Pharmacological Interventions in Bipolar Disorder.Curr Top Behav Neurosci. 2021;48:303-324. doi: 10.1007/7854_2020_181. Curr Top Behav Neurosci. 2021. PMID: 33547595 Review.
-
Neuroprotective potential of solanesol in intracerebroventricular propionic acid induced experimental model of autism: Insights from behavioral and biochemical evidence.Toxicol Rep. 2019 Nov 5;6:1164-1175. doi: 10.1016/j.toxrep.2019.10.019. eCollection 2019. Toxicol Rep. 2019. PMID: 31763180 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous